Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Keysight Technologies Inc (KEYS) Price & Performance

Amylx Pharmaceuticals IncTrade
Keysight Technologies IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Keysight Technologies Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Keysight Technologies Inc trades at $344 (market cap $57.32B). The key difference: Keysight Technologies Inc is far larger — about 22.7× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Keysight Technologies Inc nearer its low. Which is the better fit depends on your goals.

AMLXKEYS
Market Cap
$2.53B$57.32B
Sector
HealthTechnology
52-Week High
$24.19$373.34
52-Week Low
$7.82$158.51
Enterprise Value
$2.28B$57.67B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Keysight Technologies Inc

Keysight Technologies (KEYS) trades at $340.97, up 1.19% today, near its 52-week high. The stock shows strong momentum with bullish moving averages and consistent earnings beats, including Q1 2026 EPS of $2.87 versus $2.32 expected. Revenue for 2025 reached $5.38B with a net income margin of 17.31%. Recent news highlights product innovations like the APS-ONE-400 cybersecurity platform and collaborations with Intel and the European Space Agency, reinforcing growth prospects in 5G and defense markets.

Outlook remains positive with a consensus price target of $396.56, implying 16% upside, supported by 81% analyst buy ratings. Risks include elevated valuation multiples (P/E 54.91) and high RSI levels suggesting overbought conditions. Investors should monitor execution on 2026 revenue guidance of $6.1B and manage exposure to tech sector volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Keysight Technologies Inc

Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.

Read more on KEYS